In vivo immune signatures of healthy human pregnancy : inherently inflammatory or anti-inflammatory? by Graham, Caroline et al.
RESEARCH ARTICLE
In vivo immune signatures of healthy human
pregnancy: Inherently inflammatory or anti-
inflammatory?
Caroline Graham1, Rishma Chooniedass2, William P. Stefura1, Allan B. Becker1,2,3,
Malcolm R. Sears4, Stuart E. Turvey5, Piush J. Mandhane6, Padmaja Subbarao7, CHILD
Study Investigators8¶, Kent T. HayGlass1,2,3*
1 Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada, 2 Department of
Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada, 3 Children’s Hospital
Research Institute of Manitoba, Winnipeg, Manitoba, Canada, 4 Department of Medicine, de Groote School
of Medicine, McMaster University, Hamilton, Ontario, Canada, 5 Department of Pediatrics, Child & Family
Research Institute and BC Children’s Hospital, University of British Columbia, Vancouver, British Columbia,
Canada, 6 Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada, 7 Department of
Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada, 8 CHILD (Canadian
Healthy Infant Longitudinal Development Study) Investigators, McMaster University, Hamilton, Canada
¶ Membership of the CHILD Principal Investigators is provided in the Acknowledgments.
* kent.hayglass@umanitoba.ca
Abstract
Changes in maternal innate immunity during healthy human pregnancy are not well under-
stood. Whether basal immune status in vivo is largely unaffected by pregnancy, is constitu-
tively biased towards an inflammatory phenotype (transiently enhancing host defense) or
exhibits anti-inflammatory bias (reducing potential responsiveness to the fetus) is unclear.
Here, in a longitudinal study of healthy women who gave birth to healthy infants following
uncomplicated pregnancies within the Canadian Healthy Infant Longitudinal Development
(CHILD) cohort, we test the hypothesis that a progressively altered bias in resting innate
immune status develops. Women were examined during pregnancy and again, one and/or
three years postpartum. Most pro-inflammatory cytokine expression, including CCL2,
CXCL10, IL-18 and TNFα, was reduced in vivo during pregnancy (20–57%, p<0.0001). Anti-
inflammatory biomarkers (sTNF-RI, sTNF-RII, and IL-1Ra) were elevated by ~50–100%
(p<0.0001). Systemic IL-10 levels were unaltered during vs. post-pregnancy. Kinetic
studies demonstrate that while decreased pro-inflammatory biomarker expression (CCL2,
CXCL10, IL-18, and TNFα) was constant, anti-inflammatory expression increased progres-
sively with increasing gestational age (p<0.0001). We conclude that healthy resting mater-
nal immune status is characterized by an increasingly pronounced bias towards a systemic
anti-inflammatory innate phenotype during the last two trimesters of pregnancy. This is
resolved by one year postpartum in the absence of repeat pregnancy. The findings provide
enhanced understanding of immunological changes that occur in vivo during healthy human
pregnancy.
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Introduction
For healthy pregnancy to proceed to term, changes need to occur to prevent immune mediated
rejection of the semi-allogenic fetus. At the same time, the immune system must maintain, or
enhance, protection of mother and fetus from external pathogens. There is extensive literature
concerning immunity at the maternal-fetal interface and its role in progression of fetal devel-
opment [1–5]. Similarly, many studies have examined pathologic conditions that can arise
during pregnancy (i.e. preeclampsia, infection, hypoxia), often with small, cross-sectional,
healthy control groups for comparison.
Surprisingly, healthy pregnancy that leads to healthy infants has not been a major research
focus and is not well understood. Publications [6] and recent NIH workshops [7, 8] identify
the need for better insight into the biology of normal pregnancy. Attention needs to be given
to (i) understanding maternal adaptations and (ii) creating a biological definition of an opti-
mal pregnancy phenotype from fetal, maternal and paternal standpoints. Understanding puta-
tive changes in women’s in vivo innate immune status during normal pregnancy–the healthy
phenotype–will strengthen efforts to understand linkages between in vivo maternal status and
the subsequent development of healthy vs. chronic inflammatory phenotypes such as asthma
or autoimmunity in children, or their mothers, later in life [9–13].
The changes, if any, that occur in innate immune status during a healthy pregnancy are
controversial. Existing evidence supports several mutually exclusive conclusions. Some data
are consistent with the concept that basal maternal systemic immunity exhibits a mild bias
towards inflammatory phenotypes (hence, transiently enhancing host defense). Others support
the notion that immunosuppressed phenotypes (reducing potential responses to the fetus)
are normally dominant during pregnancy [14]. A third school of thought argues that innate
immune function is largely unchanged in pregnant and non-pregnant women [3, 15].
Interest in healthy pregnancy is driven by at least three other rationales. Exclusion of preg-
nant women from clinical research, while well intentioned, can be counterproductive [7].
Their inclusion requires better understanding of maternal health norms during healthy preg-
nancy. Secondly, identifying and understanding differences in basal innate immune status in
vivo during healthy pregnancy will provide better understanding of mechanisms that underlie
difficult pregnancies [15]. Finally, with extensive efforts to link systemic innate immunity in
vivo and clinical outcomes later in life for both mother and fetus [16, 17], we need to better
define immunity in healthy human pregnancy as the entry point to childhood.
The Canadian Healthy Infant Longitudinal Development (CHILD) birth cohort was initi-
ated to study the development of allergy and asthma, with a strong focus on clinical, immuno-
logic and environmental assessments of infants and parents. The 3,624 participating infants
and families are predominantly from urban centres; over 80% of the Canadian population is
urban. The cohort is multicultural and ethnically varied. Its value is enhanced by extensive
phenotyping of both children and parents, characterization of their environments and an
extensive repository of biological samples [18].
Here we test the hypothesis that resting systemic pro-/anti-inflammatory bias in vivo is
transiently shifted during pregnancy. In this longitudinal study of 251 randomly selected
healthy women who gave birth to healthy infants, pairwise comparisons were used to assess
innate immune biomarker levels in vivo during the second/third trimester then again at one
and three years postpartum. An extensive panel of pro-inflammatory cytokines that are consti-
tutively present in most healthy individuals (CCL2, CXCL10, CXCL8, IL-18, IL-6, and TNFα)
was examined. While studies of inflammatory processes often include few or no anti-inflam-
matory regulators, endogenous levels of a broad panel of anti-inflammatory cytokines (IL-10,
IL-1Ra, sTNF-RI, and sTNF-RII) were incorporated to provide a better immune signature of
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women’s health during successful pregnancy. The data reveal that extensive changes occur in
vivo. Healthy pregnancy is linked to development of a constitutive systemic anti-inflammatory
maternal bias that becomes increasingly intense with increasing gestational age, then self-
resolves by one year postpartum.
Materials and methods
Participants
The Canadian Healthy Infant Longitudinal Development (CHILD) Study is a prospective
national population-based longitudinal birth cohort of 3,624 neonates (http://www.
canadianchildstudy.ca/knowledge.html) [18]. Following written, informed consent, non-
fasting venous blood was obtained at the University of Manitoba recruitment site to yield
plasma samples from 499 women. Median age at recruitment was 31.1 years. Women were
recruited between conception and delivery, as possible, with most recruitment taking place
during the second and third trimester. Inclusion criteria included uneventful pregnancy
without documented concerns about hypertension, proteinuria or gestational diabetes that
resulted in a healthy singleton baby. Exclusion criteria included in vitro fertilization (IVF),
twins, miscarriage, intrauterine growth restriction (IUGR), clinically discernible upper respi-
ratory tract (URT) or gastrointestinal (GI) infection within a week of study visit or repeat
pregnancy evident at or within two months following one year and three year postpartum
visits. This study was approved by the University of Manitoba Human Research Ethics
Board.
To increase power, rather than incorporating unrelated non-pregnant female controls, a
longitudinal study design was used where a woman’s status during pregnancy was compared
with her own at subsequent times. Samples were obtained once at initial recruitment (a visit
between gestational weeks 10–38) and again one year postpartum. Major clinical characteris-
tics of the women studied are provided in Table 1.
251 of the mothers for whom paired plasma samples were available from prenatal (PN) and
one year post-partum (1YPP) time points (n = 331) were randomly selected for analysis of in
vivo pro- and anti-inflammatory cytokine expression (CCL2 and sTNF-RI). These biomarkers
were chosen because published, and our own preliminary data, demonstrated that readily
quantified levels are evident in >95% of healthy individuals (cf. IL-6 or IL-10 where a substan-
tial proportion of healthy individuals exhibit sub pg/ml plasma levels). For more extensive
analyses, 8 additional in vivo biomarkers were determined using approximately every second
individual (n = 120) from the original study group. Investigators were blind to any immuno-
logical data at the time of randomization and sample selection.
Table 1. Demographic and clinical characteristics of study population.
No. of Women in Study 251
Maternal Age at Delivery (years) 31.1 (18.4–43.2)
Gestational Age at PN Visit (weeks) 27.0 (9.9–38.4)
Gestational Age at Delivery (weeks) 38.0 (35.0–42.1)
Maternal Tobacco Use 5%
Preeclampsia 0% (excluded)
Gestational Diabetes Mellitus (GDM) 0% (excluded)
Values are presented as median (range) or as a percentage of the total population.
https://doi.org/10.1371/journal.pone.0177813.t001
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Among women who provided plasma samples at both one and three years post-partum,
(and who did not experience pregnancy in the interim) 32 were randomly selected to further
compare potential changes in selected plasma biomarker levels post-pregnancy (see Results).
Immunological assays
Samples were processed as described [19]. Briefly, whole blood samples were kept at room
temperature during transport and prior to processing later that day. Whole blood plasma was
collected from 10 mL sodium heparin Vacutainer tubes (BD, Mississauga, Canada) by centri-
fugation at 500g for 10 minutes, aliquoted and stored at -20˚C. Immediately prior to use in
immunological assays, thoroughly mixed plasma was subjected to a quick spin (500g, 1 min-
ute) to remove protein/lipid precipitate. Samples for pregnant and one year postpartum, or
one and three years postpartum, were analyzed as pairs on the same assay plates.
Meso Scale Discovery (MSD, Rockville, Maryland) singleplex assays were used to quantify
analyte concentrations following the manufacturer‘s instructions. Catalog numbers for the
reagent kits used are provided at Table 2.
For all assays, concentrations were determined based on standard curves created using
serial dilutions of fresh aliquots of constant recombinant lab standards prepared in culture
medium and stored at -80˚C in individual 400 uL aliquots (Cedarlane, Burlington, Canada;
PeproTech, Quebec, Canada; R&D Systems, Minneapolis, Minnesota). Longitudinal sample
sets from each individual were always paired on the same assay plates. Median intra-assay vari-
ation was typically below 5%.
Statistics
Group results are presented as medians, with each point representing the average (mean)
value obtained from duplicate or triplicate analyses of an individual woman’s plasma at that
timepoint. Supporting information S1 File contains the raw duplicates or triplicates used to
calculate the mean values for each cytokine or chemokine, for each woman, at each visit,
under each condition examined, that were then used to create the figures presented. Data for
each population were analyzed using GraphPad Prism (La Jolla, California). Pairwise compari-
sons (Wilcoxon Matched Pairs/Signed Rank tests) were used for most data sets. The Spearman
rank order correlation coefficient (non-parametric) was used to assess potential associations
between plasma biomarker levels and increasing gestational age. Differences were considered
significant at the 95% confidence level (two-tailed p<0.05).
Table 2. Catalog numbers for Meso Scale Discovery kits used in this publication.
Cytokine MSD Catalog Number
CCL2 K151AYB-2
CXCL8 K151ANB-2
CXCL10 K151NVD-2
IL-6 K151AKB-2
IL-10 K151AOB-2
IL-18 K151MCD-2
IL-1Ra N45ZA-1
sTNF-RI K151BIC-2
sTNF-RII K151BJB-2
TNFα K151BHB-2
https://doi.org/10.1371/journal.pone.0177813.t002
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Results
Alterations in basal innate immune balance are characteristic of healthy
human pregnancy
This longitudinal study aimed to determine whether the constitutive immune status of healthy
pregnant women exhibits a pro- or anti-inflammatory bias and whether it changes during
pregnancy. As described in detail at Material and Methods, plasma samples were obtained at a
single time point during pregnancy, again one year postpartum, and for a randomly obtained
subset of individuals who did not experience further pregnancies in the interim, at three years
postpartum. Two representative biomarkers of pro- and anti-inflammatory responses were
assessed initially (Fig 1). Pro-inflammatory chemokine CCL2 was readily detectible in all indi-
viduals. Among the 251 women examined, systemic CCL2 was found to be reduced by 40%
during pregnancy compared to levels one year postpartum (p<0.0001, Wilcoxon matched
pairs, medians 110 vs. 154 pg/mL). Conversely, sTNF-RI was 38% elevated during pregnancy
(medians 1,266 vs. 913, p<0.0001). Thus, the median ratio of these anti-inflammatory:pro-
inflammatory innate biomarkers (sTNF-RI:CCL2) changed from 11.4 during pregnancy to 5.9
a year following delivery. This suggests that constitutive maternal status may incline towards
an anti-inflammatory balance over the course of pregnancy.
Given the large number of pro- and anti-inflammatory cytokines and inhibitors involved in
human immune regulation, this analysis was extended in approximately every second woman
(n = 120) to a panel of five additional pro-inflammatory biomarkers (CXCL10, TNFα, IL-18,
IL-6 and CXCL8) as well as three more anti-inflammatory biomarkers (IL-10, sTNF-RII and
IL-1Ra). The cytokines selected were chosen on the basis of being (i) routinely present in the
plasma of healthy humans and (ii) having been extensively implicated in immune regulation
of inflammation in murine and human studies. These large panels of biomarkers were used in
preference to relying upon a single biomarker (CRP or IL-6 or IL-10, as is commonly done) in
order to strengthen the capacity to draw conclusions about pro- vs. anti- inflammatory bias in
vivo during pregnancy. A brief overview of the major cellular sources and biological functions
of the cytokines, chemokines and receptors studied is provided in Table 3.
Fig 2 demonstrates that during healthy pregnancy, most pro-inflammatory cytokines were
indeed reduced relative to levels in the same women one year postpartum. Thus, constitutive
CXCL10, TNFα and IL-18 were reduced during pregnancy. Median IL-6 trended lower by 42%,
but the difference did not reach statistical significance. There was no evidence of changes in con-
stitutive CXCL8 levels during healthy pregnancy. Note that due to the inherent immunological
Fig 1. Among healthy women, a systemic bias towards a resting anti-inflammatory phenotype is
evident in vivo during pregnancy. Paired plasma samples from 251 women are assessed during and one
year following healthy pregnancy. Data are presented as pg/mL. Bars represent median values of each data
set. Wilcoxon paired analyses are shown.
https://doi.org/10.1371/journal.pone.0177813.g001
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Table 3. Cytokine, chemokine and soluble receptor biomarkers examined in this publication.
Cytokine Major Sources Major Functions Major role as a Pro- or Anti-
Inflammatory immune
response modifier
CCL2
(MCP-1)
Macrophages, monocytes, endothelial cells,
fibroblasts, epithelial cells, smooth muscle cells,
mesangial cells, astrocytic cells, monocytic and
microglial cells [20].
CCL2 recruits monocytes, memory T cells, and
dendritic cells to sites of inflammation [21–23]. It has
been Implicated in pathogenesis or exacerbation of
many inflammatory diseases including asthma,
atherosclerosis, gestational diabetes mellitus,
hypertension and rheumatoid arthritis [24, 25].
Pro-Inflammatory
CXCL8
(IL-8)
Macrophages, monocytes, epithelial cells, airway
smooth muscle cells and endothelial cells [26, 27].
CXCL8 is an inflammatory chemokine involved in
neutrophil (and other granulocyte) recruitment/
chemotaxis towards sites of infection and subsequent
phagocytosis/ degranulation [27]. It is also a potent
promoter of angiogenesis [28–30].
Pro-Inflammatory
CXCL10
(IP-10)
Macrophages, monocytes, endothelial cells and
fibroblasts [31].
CXCL10 is involved in chemoattraction for monocytes/
macrophages, T cells, NK cells, and dendritic cells [32,
33]. It is also involved in the promotion of T cell
adhesion to endothelial cells, enhances Th1 activity
and has antitumor activity [32–35].
Pro-Inflammatory
IL-6 Macrophages, monocytes, T cells, endothelial cells,
placental cells and adipocytes [20, 35, 36].
In response to infection (e.g. viruses, bacteria) or
trauma (e.g. surgery, burns, tissue damage), IL-6 is
secreted and stimulates inflammation [37]. It is an
important mediator of fever, the acute phase response,
neutrophil production in bone marrow, supports B cell
growth and is antagonistic to regulatory T cells [35].
Clinically, it stimulates inflammatory processes in host
defense and many diseases including diabetes [38],
atherosclerosis [39], depression [40], Alzheimer’s [41],
systemic lupus erythematosus [42], multiple myeloma
[43], prostate cancer [44], and rheumatoid arthritis [45].
Pro-Inflammatory
IL-10 Macrophages, monocytes, T cells, B cells, NK cells,
mastocytes and adipocytes [20, 46, 47].
IL-10 inhibits T cell derived cytokine production, MHC
class II and co-stimulatory molecule expression, and
enhances B cell survival, proliferation, and antibody
production [48–52]. It inhibits TLR mediated induction
of multiple pro-inflammatory cytokines including TNFα,
IL-1β, IL-12, and IFNγ [46, 47].
Anti-Inflammatory
IL-18 Macrophages, monocytes, dendritic cells,
endothelial cells, keratinocytes and intestinal
epithelial cells [53, 54].
IL-18 induces cell-mediated immunity following
infection with microbial products (e.g. LPS) [53]. IL-18
stimulation of NK and T cells stimulates IFNγ release,
activating macrophages and other cells [55–57].
Pro-Inflammatory
IL-1Ra Macrophages, monocytes, neutrophils, mast cells,
epithelial cells and adipocytes [46, 54, 58–60].
IL-1Ra inhibits the activities of pro-inflammatory
cytokines IL-1α and IL-1β, modulating IL-1 related
immune and inflammatory responses [58, 61–63].
Anti-Inflammatory
sTNF-RI Macrophages, monocytes, T cells, B cells, NK cells,
dendritic cells, endothelial cells and epithelial cells
[46, 54, 64].
sTNF-RI is generated by the shedding of its
membrane-expressed counterpart (TNF-RI) [65]. Thus,
sTNF-RI has inherent anti-inflammatory activity, as it
competes with membrane-associated receptors for the
binding of free cytokines, confining the pro-
inflammatory cytokine activity to the local site of
inflammation [65, 66].
Anti-Inflammatory
sTNF-RII Macrophages, monocytes, T cells, B cells, NK cells,
dendritic cells, endothelial cells and epithelial cells
[46, 54, 64].
sTNF-RII is generated via shedding of a membrane-
expressed counterpart (TNF-RII) [65]. As for sTNF-RI,
it competes with membrane-associated signaling
receptors for the TNF binding, confining the pro-
inflammatory cytokine activity to the local site of
inflammation [65, 66], it has inherent anti-inflammatory
activity.
Anti-Inflammatory
TNFα Macrophages, monocytes, T cells, NK cells,
neutrophils, mast cells, eosinophils and neurons [20,
67].
TNFα is a major player in chronic and acute
inflammation [67, 68]. It also inhibits tumorigenesis and
viral replication [67]. TNFα dysregulation has been
implicated in a broad variety of human inflammatory
diseases [68, 69].
Pro-Inflammatory
https://doi.org/10.1371/journal.pone.0177813.t003
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diversity characteristic of human populations, and to avoid compression of clearly positive but
low levels of cytokine expression in some individuals, y-axis breaks are included.
Anti-inflammatory biomarkers (sTNF-RI, sTNF-RII, and IL-1Ra) demonstrated that unlike
the reductions seen in constitutive pro-inflammatory cytokine expression, anti-inflammatory
biomarker levels were elevated during pregnancy (Figs 1 and 3, p<0.0001). Interestingly,
Fig 2. Basal levels of multiple pro-inflammatory innate biomarkers are reduced in vivo during healthy
pregnancy. n = 120 longitudinal sample pairs. Bars represent median values of each data set. Wilcoxon
paired analyses are shown.
https://doi.org/10.1371/journal.pone.0177813.g002
Fig 3. Constitutive expression of multiple anti-inflammatory biomarkers is increased during
pregnancy. n = 120 longitudinal sample pairs. Bars represent median values of each data set. Wilcoxon
paired analyses are shown.
https://doi.org/10.1371/journal.pone.0177813.g003
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plasma IL-10, readily quantified in ~85% of the population, did not differ. Taken together,
the data suggest that healthy pregnancy is characterized by transiently decreased pro-, and
increased anti-inflammatory expression. This self-resolves by one year postpartum.
Validity of one year postpartum as a surrogate for the non-pregnant state
It is not logistically feasible to recruit women one year prior to an anticipated conception in
order to assess their then basal systemic immune status. We therefore addressed the possibility
that one year postpartum does not allow sufficient time for the innate immune system to return
to the non-pregnant status, hence is not an appropriate comparison group. 32 randomly
selected women who remained non-pregnant over the two years following the one year post-
partum visit were examined. At this year three visit, plasma samples were obtained and com-
pared (at the same time, in parallel assays) with plasma obtained from the same women at one
year postpartum. One pro- and one anti-inflammatory biomarker that had exhibited differen-
tial expression during pregnancy (CCL2 and IL-1Ra) and one pro- and one anti-inflammatory
biomarker that had been unchanged during pregnancy (CXCL8 and IL-10) were examined. Fig
4 demonstrates that the level of each cytokine was stable within an individual at one and three
years post-pregnancy. This supports the concept that one (or three) year postpartum samples
offer an appropriately stable comparator for non-pregnant status in this longitudinal study.
Anti-inflammatory bias is evident at least as early as the second
trimester
The comparisons above test the hypothesis that resting constitutive innate immune status is
distinct during healthy pregnancy. To better understand the kinetics of this shift in resting
immune status, the population was next stratified by trimester of recruitment. With only a
small number of women recruited during the first trimester, analysis centred on the second
Fig 4. Stability of in vivo pro- and anti-inflammatory plasma biomarkers. n = 32 longitudinal sample
pairs. Wilcoxon paired analyses are shown.
https://doi.org/10.1371/journal.pone.0177813.g004
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and third trimesters. Fig 5 demonstrates basal (i.e. healthy, resting) innate immune status is
skewed towards an anti-inflammatory phenotype at least as early as the second trimester.
The intensity of anti-inflammatory bias increases with increasing
gestational age
Finally, to determine if the intensity of anti-inflammatory phenotypic changes are altered with
the progression of pregnancy, we assessed relationships between plasma biomarker concentra-
tions and gestational age. sTNF-RI, IL-1Ra (Fig 6) and sTNF-RII (not shown) all exhibited
increasingly intense in vivo expression with increased gestational age. Conversely, the decrease
in pro-inflammatory cytokine expression (Fig 6: CCL2 and IL-18; data not shown: CXCL8,
CXCL10, IL-6 and TNFα) was constant and exhibited no relationship with increasing gesta-
tional age. Thus, the shift towards an increasingly anti-inflammatory bias intensified with
increasing gestational age during healthy pregnancy.
Fig 5. Longitudinal analysis of differences in pro- and anti-inflammatory cytokines in second and
third trimesters. Independent panels of volunteers were examined during the second or third trimester and
compared with levels one year postpartum. Bars represent median values of each data set. Wilcoxon paired
analyses are shown.
https://doi.org/10.1371/journal.pone.0177813.g005
Fig 6. Relationships between gestational age and intensity of anti-inflammatory or pro-inflammatory
plasma biomarker expression. Spearman regression analyses are shown.
https://doi.org/10.1371/journal.pone.0177813.g006
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Discussion
Although most pregnancies lead to healthy infants, prior research has focused heavily on dis-
eases of pregnancy. Here, maternal health was examined in 251 healthy pregnant women over
up to three years. The data reveal that at least as early as the second trimester, women exhibit
increasingly strong constitutive expression of anti-inflammatory mediators and reduced
expression of many, but not all, cytokines linked to host defense and inflammatory immune
capacity. This transient anti-inflammatory phenotype intensifies with increasing gestational
age and is self-resolving by one year postpartum.
Our primary focus here is maternal health and the systemic, constitutive innate immune sta-
tus exhibited by women during pregnancy. This is not an investigation of factors which enable
pregnancy to become established, to proceed to term, or to respond to acute viral or bacterial
infection. There is a longstanding lack of agreement regarding constitutive innate immune sta-
tus during a healthy pregnancy. Small cohorts of healthy pregnant women are incorporated in
most studies that examine diseases of pregnancy. In those studies, cross-sectional comparisons
are drawn with a broad range of difficult pregnancies, rather than explicitly using well-powered
longitudinal study designs to examine the status of healthy women during vs. post-pregnancy.
Not surprisingly, such studies do not provide a clear consensus. One school argues that systemic
immune status in vivo, unlike immune status at the maternal/fetal interface, reflects a general-
ized mild inflammatory response [70–73]. Others argue for the dominance of anti-inflamma-
tory responses [74, 75]. These apparent contradictions may be due to cross-sectional study
designs, cohorts of relatively small size, the resulting impact of subject to subject variability, and
reliance on a small number of biomarkers (often one) to assess innate immune bias in vivo. For
example, two of the largest longitudinal studies available [76, 77] are composed of 48 and 21
healthy women respectively who are followed through pregnancy and postpartum. Many stud-
ies involve different ethnicities: Kraus included a 94% Hispanic/Black population [76], while
Szarka utilized a Caucasian population [78]. As pointed out more than two decades ago [79],
due to high inter-subject variability inherent to any outbred population, a longitudinal,
matched study design involving a large n is logistically challenging, but highly important.
This research has important caveats. Firstly, because a longitudinal, multi-year study design
was selected to achieve increased sensitivity, it was not socially or logistically feasible to recruit
individuals prior to an anticipated pregnancy. For this reason, pregnant women were com-
pared with their immune status at one year and, for a subset, three years postpartum. Pre-preg-
nancy immune status could not be directly determined. Secondly, a potential confounder that
cannot be ruled out is the impact of specific environmental antigens and pathogens on these
findings. Women with complicated pregnancies with known linkages to altered innate immu-
nity (i.e. preeclampsia) are excluded from this study. Among the women studied, clinical
assessments at each blood draw excluded women with active transient URT or GI infections.
The data reported above, characterizing the constitutive in vivo phenotype of healthy normal
pregnancy positions us to better assess the impact of environmental and genetic influences in
pregnancy in subsequent studies. A third caveat is that the impact of menstrual stage postpar-
tum at sampling could influence some values obtained. This underlines the need for sufficient
power because the impact of such variables is increasingly reduced as the number of individu-
als examined increases.
A potential confounder to interpretation of the data obtained was day-to-day stability of
biomarker expression within a given individual. We found this to have minimal impact
because, as shown in Fig 4, and as was previously reported in short-term studies conducted in
men and non-pregnant women [76, 80], systemic levels of most biomarkers are remarkably
stable across time (days-weeks) in healthy individuals.
Constitutive innate immune status during healthy pregnancy
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The immunological and clinical implications that result from the increasingly pronounced
anti-inflammatory phenotype that developed over the course of healthy pregnancy remains
speculative. Extensive literature demonstrates associations between pro-inflammatory or type
1 cytokines and recurrent spontaneous miscarriage or preterm delivery. Exogenous TNFα and
IFN inhibit the outgrowth of human trophoblasts in vitro and induce apoptosis of human vil-
lous trophoblast cells. Murine studies demonstrate that administration of pro-inflammatory
cytokines (i.e. TNFα, IFN, IL-2) into pregnant mice causes increased abortion. Conversely,
administration of IL-10 prevents fetal wastage in abortion-prone mice [81, 82]. Thus, there is
consensus that controls on excessive pro-inflammatory innate responses are essential for suc-
cessful pregnancy [75].
These data may stand in contrast to in vivo expression of acute phase proteins during
healthy pregnancy. Multiple studies have found increased plasma/serum CRP levels vs. non-
pregnant controls [83–86]. The extent to which changes in this largely IL-6 and TNFα driven
biomarker of inflammation are due to activation of classical innate immune responses or
other cells (i.e. adipocytes or necrotic processes associated with placenta ageing) is under active
investigation [83, 87, 88]. Interestingly, several groups have found undetectable changes or
decreases in CRP over the course of healthy pregnancy [83, 89–92]. This inconsistency, and
the many pregnancy independent factors (i.e. obesity) that can influence CRP levels, under-
lines a need for caution and continued research prior to drawing mechanistic conclusions
about the role any of these mediators play in successful conclusion of pregnancy.
In this study, we do not address putative differences in maternal immune responses upon
infection in vivo or acute in vitro activation. Studies examining in vitro responses to various
pattern recognition receptor (PRR) ligands are currently underway as a complementary
approach to understanding changes in maternal health that can occur during pregnancy.
With increasing attention given to defining what constitutes a healthy pregnancy [93], this
study provides valuable insight into systemic innate immune changes that result in expression
of an increasingly intense anti-inflammatory phenotype in vivo during pregnancy. It under-
lines the need for further characterization of what constitutes a successful environment for
healthy human pregnancy.
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